Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review

被引:45
作者
Anghel, Laura-Alexandra [1 ]
Farcas, Andreea Maria [2 ]
Oprean, Radu Nicolae [1 ]
机构
[1] Univ Med & Pharm Iuliu Hatieganu, Fac Pharm, Dept Analyt Chem & Instrumental Anal, Cluj Napoca, Romania
[2] Univ Med & Pharm Iuliu Hatieganu, Drug Informat Res Ctr, Cluj Napoca, Romania
来源
PATIENT PREFERENCE AND ADHERENCE | 2018年 / 12卷
关键词
drug therapy; rheumatology; patient nonadherence; risk factors; MODIFYING ANTIRHEUMATIC DRUGS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ALPHA INHIBITOR TREATMENT; PSORIATIC-ARTHRITIS; ANKYLOSING-SPONDYLITIS; EULAR RECOMMENDATIONS; BIOLOGIC THERAPIES; TOBACCO SMOKING; BELIEFS; DETERMINANTS;
D O I
10.2147/PPA.S165101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Several drugs are available for the treatment of autoimmune rheumatic diseases; however, their effectiveness may be negatively influenced by inappropriate adherence. Low adherence and persistence rates have a significant impact on patient quality of life and are associated with health-related expenses. Purpose: To provide an up-to-date narrative review on treatment adherence and persistence rates, and discuss the factors that influence them, in patients with autoimmune rheumatic diseases. Materials and methods: We searched the PubMed database for studies among patients with a diagnosis of rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), or psoriatic arthritis (PsA), published from January 2015 to February 2017. Only studies with a well-defined measurement of adherence/persistence and those that carried out an evaluation of the influencing factors were included. Results: Fifteen relevant studies that evaluated adherence and/or persistence were included. Adherence rates varied between 9.3% and 94%, and persistence rates between 23% and 80%. Most of the studies used one method to evaluate adherence or persistence (different questionnaire scores, proportion of days covered, and mean treatment duration). A high concordance was found between the adherence measurements of the Medication Event Monitoring System and Visual Analog Scale. Factors of economic, demographic, and clinical nature were only moderately linked to treatment adherence or persistence. However, patient-related factors - such as positive and increased beliefs in medication necessity, strong views of the chronic nature of the diseases, and increased knowledge of the disease - were related to better treatment adherence. Conclusion: Owing to the heterogeneity of the study results, we consider that the use of more than one method to assess adherence/persistence should yield more comprehensive and accurate data about patient adherence behavior. Patient-related factors should be included and analyzed more often in adherence studies as the former may be modified to improve patient adherence.
引用
收藏
页码:1151 / 1166
页数:16
相关论文
共 59 条
[1]   Determinants of medication non-adherence in Egyptian patients with systemic lupus erythematosus: Sharkia Governorate [J].
Abdul-Sattar, Amal B. ;
Abou El Magd, Sahar A. .
RHEUMATOLOGY INTERNATIONAL, 2015, 35 (06) :1045-1051
[2]  
[Anonymous], 2013, Adherence to Long-Term Therapies: Evidence for Action, DOI DOI 10.4028/WWW.SCIENTIFIC.NET/AMM.321-324.1779
[3]   EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics [J].
Bertsias, G. ;
Ioannidis, J. P. A. ;
Boletis, J. ;
Bombardieri, S. ;
Cervera, R. ;
Dostal, C. ;
Font, J. ;
Gilboe, I. M. ;
Houssiau, F. ;
Huizinga, T. ;
Isenberg, D. ;
Kallenberg, C. G. M. ;
Khamashta, M. ;
Piette, J. C. ;
Schneider, M. ;
Smolen, J. ;
Sturfelt, G. ;
Tincani, A. ;
van Vollenhoven, R. ;
Gordon, C. ;
Boumpas, D. T. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) :195-205
[4]   Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients' Adherence Using a Self-report Questionnaire [J].
Betegnie, Anne-Laure ;
Gauchet, Aurelie ;
Lehmann, Audrey ;
Grange, Laurent ;
Roustit, Matthieu ;
Baudrant, Magalie ;
Bedouch, Pierrick ;
Allenet, Benoit .
JOURNAL OF RHEUMATOLOGY, 2016, 43 (04) :724-730
[5]   Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis [J].
Bonafede, Machaon ;
Johnson, Barbara H. ;
Tang, Derek H. ;
Shah, Neel ;
Harrison, David J. ;
Collier, David H. .
ARTHRITIS CARE & RESEARCH, 2015, 67 (12) :1656-1663
[6]   Medication Adherence: WHO Cares? [J].
Brown, Marie T. ;
Bussell, Jennifer K. .
MAYO CLINIC PROCEEDINGS, 2011, 86 (04) :304-314
[7]   Predictors of adherence with antihypertensive and lipid-lowering therapy [J].
Chapman, RH ;
Benner, JS ;
Petrilla, AA ;
Tierce, JC ;
Collins, SR ;
Battleman, DS ;
Schwartz, JS .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) :1147-1152
[8]   Medication Adherence and Attrition to Biologic Treatment in Rheumatoid Arthritis Patients [J].
Chu, Li-Hao ;
Kawatkar, Aniket A. ;
Gabriel, Sherine E. .
CLINICAL THERAPEUTICS, 2015, 37 (03) :660-666
[9]   Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: Application of the Necessity-Concerns Frarnework [J].
Clifford, Sarah ;
Barber, Nick ;
Horne, Rob .
JOURNAL OF PSYCHOSOMATIC RESEARCH, 2008, 64 (01) :41-46
[10]   Adherence to treatment in systemic lupus erythematosus patients [J].
Costedoat-Chalumeau, Nathalie ;
Pouchot, Jacques ;
Guettrot-Imbert, Gaelle ;
Le Guern, Veronique ;
Leroux, Gaelle ;
Marra, Donata ;
Morel, Nathalie ;
Piette, Jean-Charles .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2013, 27 (03) :329-340